|
|
Chinese herbal medicine reduces mortality in patients with severe and critical coronavirus disease 2019: a retrospective cohort study |
Guohua Chen1, Wen Su1, Jiayao Yang1, Dan Luo1, Ping Xia1, Wen Jia1, Xiuyang Li2, Chuan Wang1, Suping Lang3, Qingbin Meng1, Ying Zhang4, Yuhe Ke1, An Fan3, Shuo Yang1, Yujiao Zheng2, Xuepeng Fan1, Jie Qiao5, Fengmei Lian2(), Li Wei1(), Xiaolin Tong2() |
1. Wuhan No.1 Hospital (Wuhan Integrated TCM & Western Medicine Hospital), Wuhan 430022, China 2. Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China 3. GCP ClinPlus Co., Ltd., Beijing 100160, China 4. Beijing University of Chinese Medicine, Beijing 100029, China 5. Hubei University of Traditional Chinese Medicine, Wuhan 430060, China |
|
|
Abstract This study aimed to evaluate the efficacy of Chinese herbal medicine (CHM) in patients with severe/critical coronavirus disease 2019 (COVID-19). In this retrospective study, data were collected from 662 patients with severe/critical COVID-19 who were admitted to a designated hospital to treat patients with severe COVID-19 in Wuhan before March 20, 2020. All patients were divided into an exposed group (CHM users) and a control group (non-users). After propensity score matching in a 1:1 ratio, 156 CHM users were matched by propensity score to 156 non-users. No significant differences in seven baseline clinical variables were found between the two groups of patients. All-cause mortality was reported in 13 CHM users who died and 36 non-users who died. After multivariate adjustment, the mortality risk of CHM users was reduced by 82.2% (odds ratio 0.178, 95% CI 0.076–0.418; P<0.001) compared with the non-users. Secondly, age (odds ratio 1.053, 95% CI 1.023–1.084; P<0.001) and the proportion of severe/critical patients (odds ratio 0.063, 95% CI 0.028–0.143; P<0.001) were the risk factors of mortality. These results show that the use of CHM may reduce the mortality of patients with severe/critical COVID-19.
|
Keywords
COVID-19
CHM
mortality
a retrospective cohort study
|
Corresponding Author(s):
Fengmei Lian,Li Wei,Xiaolin Tong
|
Just Accepted Date: 12 August 2020
Online First Date: 14 September 2020
Issue Date: 24 December 2020
|
|
1 |
C Sohrabi, Z Alsafi, N O'Neill, M Khan, A Kerwan, A Al-Jabir, C Iosifidis, R Agha. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). INT J SURG 2020; 76:71–76
https://doi.org/10.1016/j.ijsu.2020.02.034
pmid: 32112977
|
2 |
DD Rajgor, MH Lee, S Archuleta, N Bagdasarian, SC Quek. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis 2020; 20(7): 776–777
https://doi.org/10.1016/S1473-3099(20)30244-9
pmid: 32224313
|
3 |
World Health Organization. Coronavirus disease 2019 (COVID-19) situation report–69. 2020. (accessed March 20, 2020)
|
4 |
X Yang, Y Yu, J Xu, H Shu, J Xia, H Liu, Y Wu, L Zhang, Z Yu, M Fang, T Yu, Y Wang, S Pan, X Zou, S Yuan, Y Shang. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8(5): 475–481
https://doi.org/10.1016/S2213-2600(20)30079-5
pmid: 32105632
|
5 |
B Cao, Y Wang, D Wen, W Liu, J Wang, G Fan, L Ruan, B Song, Y Cai, M Wei, X Li, J Xia, N Chen, J Xiang, T Yu, T Bai, X Xie, L Zhang, C Li, Y Yuan, H Chen, H Li, H Huang, S Tu, F Gong, Y Liu, Y Wei, C Dong, F Zhou, X Gu, J Xu, Z Liu, Y Zhang, H Li, L Shang, K Wang, K Li, X Zhou, X Dong, Z Qu, S Lu, X Hu, S Ruan, S Luo, J Wu, L Peng, F Cheng, L Pan, J Zou, C Jia, J Wang, X Liu, S Wang, X Wu, Q Ge, J He, H Zhan, F Qiu, L Guo, C Huang, T Jaki, FG Hayden, PW Horby, D Zhang, C Wang. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020; 382(19): 1787–1799
https://doi.org/10.1056/NEJMoa2001282
pmid: 32187464
|
6 |
K Zhang. Is traditional Chinese medicine useful in the treatment of COVID-19? Am J Emerg Med 2020; [Epub ahead of print] doi: 10.1016/j.ajem.2020.03.046
https://doi.org/10.1016/j.ajem.2020.03.046
pmid: 32245701
|
7 |
National Health Commission of the People’s Republic of China. Notice on the issuance of the fifth edition of the Diagnosis and Treatment Guideline for COVID-19 (Trial Version). 2020. (in Chinese) (accessed February 5, 2020)
|
8 |
F Zhou, T Yu, R Du, G Fan, Y Liu, Z Liu, J Xiang, Y Wang, B Song, X Gu, L Guan, Y Wei, H Li, X Wu, J Xu, S Tu, Y Zhang, H Chen, B Cao. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054–1062
https://doi.org/10.1016/S0140-6736(20)30566-3
pmid: 32171076
|
9 |
C Wu, X Chen, Y Cai, J Xia, X Zhou, S Xu, H Huang, L Zhang, X Zhou, C Du, Y Zhang, J Song, S Wang, Y Chao, Z Yang, J Xu, X Zhou, D Chen, W Xiong, L Xu, F Zhou, J Jiang, C Bai, J Zheng, Y Song. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180(7): 934
https://doi.org/10.1001/jamainternmed.2020.0994
pmid: 32167524
|
10 |
D Wang, B Hu, C Hu, F Zhu, X Liu, J Zhang, B Wang, H Xiang, Z Cheng, Y Xiong, Y Zhao, Y Li, X Wang, Z Peng. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061
https://doi.org/10.1001/jama.2020.1585
pmid: 32031570
|
11 |
L Runfeng, H Yunlong, H Jicheng, P Weiqi, M Qinhai, S Yongxia, L Chufang, Z Jin, J Zhenhua, J Haiming, Z Kui, H Shuxiang, D Jun, L Xiaobo, H Xiaotao, W Lin, Z Nanshan, Y Zifeng. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020; 156: 104761
https://doi.org/10.1016/j.phrs.2020.104761
pmid: 32205232
|
12 |
W Zhang, Y Zhao, F Zhang, Q Wang, T Li, Z Liu, J Wang, Y Qin, X Zhang, X Yan, X Zeng, S Zhang. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol 2020; 214: 108393
https://doi.org/10.1016/j.clim.2020.108393
pmid: 32222466
|
13 |
G Li, E De Clercq. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020; 19(3): 149–150
https://doi.org/10.1038/d41573-020-00016-0
pmid: 32127666
|
14 |
L Deng, C Li, Q Zeng, X Liu, X Li, H Zhang, Z Hong, J Xia. Arbidol combined with LPV/r versus LPV/r alone against coronavirus disease 2019: a retrospective cohort study. J Infect 2020; 81(1): e1–e5
https://doi.org/10.1016/j.jinf.2020.03.002
pmid: 32171872
|
15 |
JA Al-Tawfiq, AH Al-Homoud, ZA Memish. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 2020; 34: 101615
https://doi.org/10.1016/j.tmaid.2020.101615
pmid: 32145386
|
16 |
M Wang, R Cao, L Zhang, X Yang, J Liu, M Xu, Z Shi, Z Hu, W Zhong, G Xiao. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269–271
https://doi.org/10.1038/s41422-020-0282-0
pmid: 32020029
|
17 |
JL Ren, AH Zhang, XJ Wang. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res 2020; 155: 104743
https://doi.org/10.1016/j.phrs.2020.104743
pmid: 32145402
|
18 |
L Ni, L Zhou, M Zhou, J Zhao, DW Wang. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Front Med 2020; 14(2): 210–214
https://doi.org/10.1007/s11684-020-0757-x
pmid: 32170559
|
19 |
Z Wang, X Chen, Y Lu, F Chen, W Zhang. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020; 14(1): 64–68
https://doi.org/10.5582/bst.2020.01030
pmid: 32037389
|
20 |
B Waldeck, E Widmark. The interaction of ephedrine with β-adrenoceptors in tracheal, cardiac and skeletal muscles. Clin Exp Pharmacol Physiol 1985; 12(4): 439–442
https://doi.org/10.1111/j.1440-1681.1985.tb00891.x
pmid: 3004791
|
21 |
HK Chang, HY Yang, TH Lee, MC Shin, MH Lee, MS Shin, CJ Kim, OJ Kim, SP Hong, S Cho. Armeniacae semen extract suppresses lipopolysaccharide-induced expressions of cyclooxygenase [correction of cycloosygenase]-2 and inducible nitric oxide synthase in mouse BV2 microglial cells. Biol Pharm Bull 2005; 28(3): 449–454
https://doi.org/10.1248/bpb.28.449
pmid: 15744067
|
22 |
SM Sun, YM Song, J Liu, SR Yu. Pharmacological effects of volatile compounds from Eupatorium fortunei Turcz. Nothwest Pharm J (Xi Bei Yao Xue Za Zhi) 1995; 10: 24–26 (in Chinese)
|
23 |
HH Shen, K Wang, W Li, YH Ying, GX Gao, XB Li, HQ Huang. Astragalus membranaceus prevents airway hyperreactivity in mice related to Th2 response inhibition. J Ethnopharmacol 2008; 116(2): 363–369
https://doi.org/10.1016/j.jep.2007.12.002
pmid: 18226482
|
24 |
YC Li, YF Xian, ZR Su, SP Ip, JH Xie, JB Liao, DW Wu, CW Li, JN Chen, ZX Lin, XP Lai. Pogostone suppresses proinflammatory mediator production and protects against endotoxic shock in mice. J Ethnopharmacol 2014; 157: 212–221
https://doi.org/10.1016/j.jep.2014.09.023
pmid: 25256685
|
25 |
S Hyuga, M Hyuga, N Oshima, T Maruyama, H Kamakura, T Yamashita, M Yoshimura, Y Amakura, T Hakamatsuka, H Odaguchi, Y Goda, T Hanawa. Ephedrine alkaloids-free Ephedra Herb extract: a safer alternative to ephedra with comparable analgesic, anticancer, and anti-influenza activities. J Nat Med 2016; 70(3): 571–583
https://doi.org/10.1007/s11418-016-0979-z
pmid: 26943796
|
26 |
J Fu, Z Wang, L Huang, S Zheng, D Wang, S Chen, H Zhang, S Yang. Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi). Phytother Res 2014; 28(9): 1275–1283
https://doi.org/10.1002/ptr.5188
pmid: 25087616
|
27 |
D Liu, L Chen, J Zhao, K Cui. Cardioprotection activity and mechanism of Astragalus polysaccharide in vivo and in vitro. Int J Biol Macromol 2018; 111: 947–952
https://doi.org/10.1016/j.ijbiomac.2018.01.048
pmid: 29329811
|
28 |
Z Li, L Zhu, H Zhang, J Yang, J Zhao, D Du, J Meng, F Yang, Y Zhao, J Sun. Protective effect of a polysaccharide from stem of Codonopsis pilosula against renal ischemia/reperfusion injury in rats. Carbohydr Polym 2012; 90(4): 1739–1743
https://doi.org/10.1016/j.carbpol.2012.07.062
pmid: 22944441
|
29 |
C Liu, J Chen, E Li, Q Fan, D Wang, P Li, X Li, X Chen, S Qiu, Z Gao, H Li, Y Hu. The comparison of antioxidative and hepatoprotective activities of Codonopsis pilosula polysaccharide (CP) and sulfated CP. Int Immunopharmacol 2015; 24(2): 299–305
https://doi.org/10.1016/j.intimp.2014.12.023
pmid: 25543057
|
30 |
JC Lee, KY Lee, YO Son, KC Choi, J Kim, SH Kim, GH Chung, YS Jang. Stimulating effects on mouse splenocytes of glycoproteins from the herbal medicine Atractylodes macrocephala Koidz. Phytomedicine 2007; 14(6): 390–395
https://doi.org/10.1016/j.phymed.2006.09.012
pmid: 17084605
|
31 |
Y Sun. Biological activities and potential health benefits of polysaccharides from Poria cocos and their derivatives. Int J Biol Macromol 2014; 68: 131–134
https://doi.org/10.1016/j.ijbiomac.2014.04.010
pmid: 24751506
|
32 |
JL Ríos. Chemical constituents and pharmacological properties of Poria cocos. Planta Med 2011; 77(7): 681–691
https://doi.org/10.1055/s-0030-1270823
pmid: 21347995
|
33 |
C Wang, H Ming, W Jia, W Su, LR Zhang, D Luo, JY Yang. Analysis on medication regularity and pharmacodynamic characteristics of traditional Chinese medicine treatment of 444 severe cases of COVID-19. China J Chin Materia Medica (Zhongguo Zhong Yao Za Zhi) 2020; [Epub ahead of print] doi:10.19540/j.cnki.cjcmm.20200427.501 (in Chinese)
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|